213 related articles for article (PubMed ID: 31678641)
1. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
[TBL] [Abstract][Full Text] [Related]
2. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Mao JJ; Su HI; Feng R; Donelson ML; Aplenc R; Rebbeck TR; Stanczyk F; DeMichele A
Breast Cancer Res; 2011 Jan; 13(1):R8. PubMed ID: 21251330
[TBL] [Abstract][Full Text] [Related]
3. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Mao JJ; Stricker C; Bruner D; Xie S; Bowman MA; Farrar JT; Greene BT; DeMichele A
Cancer; 2009 Aug; 115(16):3631-9. PubMed ID: 19517460
[TBL] [Abstract][Full Text] [Related]
4. Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Reinbolt RE; Sonis S; Timmers CD; Fernández-Martínez JL; Cernea A; de Andrés-Galiana EJ; Hashemi S; Miller K; Pilarski R; Lustberg MB
Cancer Med; 2018 Jan; 7(1):240-253. PubMed ID: 29168353
[TBL] [Abstract][Full Text] [Related]
5. Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Nyrop KA; Callahan LF; Cleveland RJ; Arbeeva LL; Hackney BS; Muss HB
Oncologist; 2017 Oct; 22(10):1238-1249. PubMed ID: 28698390
[TBL] [Abstract][Full Text] [Related]
6. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
[TBL] [Abstract][Full Text] [Related]
8. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
Desai K; Mao JJ; Su I; Demichele A; Li Q; Xie SX; Gehrman PR
Support Care Cancer; 2013 Jan; 21(1):43-51. PubMed ID: 22584732
[TBL] [Abstract][Full Text] [Related]
10. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias.
Galantino ML; Desai K; Greene L; Demichele A; Stricker CT; Mao JJ
Integr Cancer Ther; 2012 Dec; 11(4):313-20. PubMed ID: 21733988
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
12. A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.
Galantino ML; Greene L; Archetto B; Baumgartner M; Hassall P; Murphy JK; Umstetter J; Desai K
Explore (NY); 2012; 8(1):40-7. PubMed ID: 22225932
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors.
Mao H; Bao T; Shen X; Li Q; Seluzicki C; Im EO; Mao JJ
Eur J Cancer; 2018 Sep; 101():47-54. PubMed ID: 30014974
[TBL] [Abstract][Full Text] [Related]
14. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
[TBL] [Abstract][Full Text] [Related]
15. Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
Galantino ML; Callens ML; Cardena GJ; Piela NL; Mao JJ
Altern Ther Health Med; 2013; 19(6):38-44. PubMed ID: 24254037
[TBL] [Abstract][Full Text] [Related]
16. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
[TBL] [Abstract][Full Text] [Related]
17. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
18. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Chim K; Xie SX; Stricker CT; Li QS; Gross R; Farrar JT; DeMichele A; Mao JJ
BMC Cancer; 2013 Sep; 13():401. PubMed ID: 24004677
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
